

Ovarian Cancer: Identifying and Managing Familial and Genetic Risk Committee meeting 8

Date: 13/12/2022

Location: Virtually via Zoom

Minutes: Confirmed

Committee members present:	
Alison Cameron (Chair)	(Present for notes 1 – 8)
Ranjit Manchanda (Topic Advisor)	(Present for notes 5 – 8)
Victoria Barber	(Present for notes 1 – 8)
Adam Brentnall	(Present for notes 1 – 8)
Rebecca Bowen	(Present for notes 1 – 8)
Melanie Davies	(Present for notes 1 – 8)
Gareth Evans	(Present for notes 5 – 8)
Judith Hayward	(Present for notes 1 – 8)
Tracie Miles	(Present for notes 1 – 8)
Davina Moses	(Present for notes 1 – 8)
Fiona Robb	(Present for notes 1 – 8)
Adam Rosenthal	(Present for notes 1 – 8)
Lucy Side	(Present for notes 1 – 8)
Vishakha Tripathi	(Present for notes 2 – 8)
Mark Davies	(Present for notes 2 – 4 and 6 – 8)
Britta Stordal	(Present for notes 2 – 7)

In attendance:		
Katharina Dworzynski	Guideline Lead	(Present for notes 1 – 8)
Hayley Shaw	Project Manager	(Present for notes 1 – 8)
Nathan Bromham	Senior Systematic Reviewer	(Present for notes 1 – 8)
Laura Berg	Systematic Reviewer	(Present for notes 1 – 8)
Katriona O'Donoghue	Systematic Reviewer	(Present for notes 1 – 8)
Suhayl Kassam	Systematic Reviewer	(Present for notes 1 – 8)
Eric Slade	Senior Health Economist	(Present for notes 1 – 8)
Nick O'Callaghan-Staples	Guideline Commissioning	(Present for notes 3 – 8)

	Manager	
--	---------	--

Apologies:	
Joanne Stanford	Committee member (Lay)
Glenn McCluggage	Committee member
Sarah Palombella	Senior Medical Editor
Emma Clegg	Information Scientist
Steve Pilling	Clinical Advisor
Neil Ryan	Clinical Fellow
Tara Chernick	Adoption and Implementation Manager

Not in attendance	
Ranjit Manchanda	(Topic Advisor) – items 1 – 4
Gareth Evans	Committee member – items 1 – 4

1. Welcome, housekeeping, aims of the day and apologies							
<p>The Chair welcomed the committee members and attendees to the 8th meeting on Ovarian Cancer: Identifying and Managing Familial and Genetic Risk.</p> <p>The Chair informed the committee that apologies had been received. These are noted above.</p> <p>The Chair outlined the meeting objectives.</p>							
2. Confirmation of matter under discussion, and declarations of interest							
<p>The Chair asked everyone to verbally declare any interests that have risen since the last meeting. New interests were declared as noted below. Two members of the committee, Ranjit Manchanda and Gareth Evans, were excluded from the morning's items related to 4.1 and 4.3, this is due to previous declared interests by both members precluding them from participating in the first half of this meeting.</p>							
Name	Role	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Dr Victoria	Committee	Direct non-financial profession	Involved in preliminary	April 2022	October 2022	29/12/2022	Declare and participate

Barber	member	al and personal interest	y discussion s regarding Target Ovarian Cancer pathfinder study				Agreed by GL and GC December 2022 Rationale: Whilst this study is relevant to the information and support topic of the guideline, it was not included as evidence. The committee member's involvement in the study was also preliminary rather than being involved as a main author.
3. Minutes of the last meeting							
The Chair asked the committee to confirm the minutes of the last meeting, and the committee confirmed no changes were required.							
4. Morning presentations							
Eric Slade, Senior Health Economist, provided an update on the economics for 4.1. The Chair introduced Laura Berg, Systematic Reviewer and Mark Davies, Topic Group Lead, who presented evidence review question 4.3: Which populations with a high prevalence of pathogenic variants would meet the risk threshold for genetic testing?							
5. Lay member forum							
Lay members were given the opportunity to reflect and make any suggestions or							

comments to the other committee members.

6. Afternoon presentations

The Chair introduced Katriona O'Donoghue, Systematic Reviewer, Suhayl Kassam, Systematic Reviewer, and Fiona Robb, Topic Group Lead, who presented evidence review question 1.1: What information and support is needed by women with familial ovarian cancer or who are at increased risk of ovarian cancer (with or without breast cancer), and their families and carers?

7. Questions and discussion

The committee discussed:

- The evidence presented for evidence review questions 4.3 and 1.1
- Economic model for 4.1

8. Any other business and summary of actions

Katharina Dworzynski summarised the actions and confirmed the topics for the next meeting.

No other business was discussed.

The Chair closed the meeting at 16:30.

Date of next meeting: 01/02/2023

Location of next meeting: Via Zoom.